What is Terlipressin?
Terlipressin is a vasopressin-related medicine used in a specific hepatorenal-syndrome setting. Its kidney-function results must be considered with the risk of serious respiratory complications.
Biological role or research focus
Hepatorenal syndrome and circulatory physiology.
Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result.
Role reference: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
- Class / identity
- Vasopressin analogue
- Research focus
- Hepatorenal syndrome and circulatory physiology
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
Quick answers
- Is Terlipressin FDA approved?
- Yes. Terlivaz (NDA 022231, approved September 2022) to improve kidney function in adults with hepatorenal syndrome. Source ↗
- Is Terlipressin safe?
- Terlipressin is a hospital drug for hepatorenal syndrome; its boxed warning covers serious or fatal breathing failure, and it can also cut off blood flow to the heart, gut or limbs. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Terlipressin banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S5 Diuretics and masking agents). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| CONFIRM (2021) | Human randomized trial | 300 adults with type 1 hepatorenal syndrome, randomized 199 to terlipressin and 101 to placebo. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2021
CONFIRM
Did hepatorenal-syndrome reversal improve, and what happened to mortality?
- Population / model
- 300 adults with type 1 hepatorenal syndrome, randomized 199 to terlipressin and 101 to placebo.
- Study design
- Randomized placebo-controlled phase 3 trial; albumin was strongly recommended in both groups.
- Main finding
- Verified hepatorenal-syndrome reversal occurred in 32% versus 17%. At 90 days, deaths occurred in 51% versus 45%; respiratory-disorder deaths occurred in 11% versus 2%.
- Limits & context
- Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result.
Source: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
76 registered studies name Terlipressin as an intervention among the 100 most recently updated of 116 search results; 4 are recruiting or under way, 3 have not started recruiting yet, 38 completed and 31 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 76 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Editorial musings. ↗
JHEP reports : innovation in hepatology · 2019 Aug · Editorial
Read available full text ↗
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. ↗
Hepatology (Baltimore, Md.) · 2016 Mar · Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
Terlipressin Acetate. ↗
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023 Jan 1 · Journal Article
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. ↗
Hepatology (Baltimore, Md.) · 2015 Aug · Comparative Study, Journal Article, Randomized Controlled Trial
Risks & interactions
Terlipressin is a hospital drug for hepatorenal syndrome; its boxed warning covers serious or fatal breathing failure, and it can also cut off blood flow to the heart, gut or limbs.
Can cause serious or fatal respiratory failure. People with fluid overload or the most severe acute-on-chronic liver failure are at higher risk, and it should not be started in someone with low oxygen levels.
Safety is established by FDA labeling based mainly on one placebo-controlled trial in hospitalized patients, where serious or fatal respiratory failure occurred in about one in seven treated patients versus one in twenty on placebo.
Take extra care with: Heart or blood pressure problemsPregnancy or breastfeedingLiver problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Low oxygen levels or worsening breathing symptoms
- Ongoing heart, limb or gut (mesenteric) ischemia
- Most severe acute-on-chronic liver failure (Grade 3): label says avoid
- History of severe heart, blood-vessel or stroke disease: label says avoid
Serious risks
- Serious or fatal respiratory failure
- Ischemic events in the heart, brain, gut or limbs
- Side effects that may make a patient ineligible for a liver transplant
- Possible harm to an unborn baby
Common side effects
- abdominal pain
- nausea
- diarrhea
- shortness of breath
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Terlivaz (terlipressin) prescribing information ↗
What the featured evidence can tell us
MedlinePlus warns of severe or life-threatening breathing problems. Patient selection and monitoring require clinical assessment; renal endpoint improvement is not sufficient to characterize overall benefit-risk.
Source: MedlinePlus · Terlipressin injection ↗
Identity, route, and evidence limits
Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result.
Source: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
Regulatory status
- U.S. FDA approval
- Approved
Terlivaz (NDA 022231, approved September 2022) to improve kidney function in adults with hepatorenal syndrome. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S5 Diuretics and masking agents
Not named. S5 names desmopressin and covers "other substances with a similar chemical structure or similar biological effect(s)", with an explicit exception only for dental felypressin, so vasopressin analogues are likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
Terlipressin is a prescription treatment used to improve kidney function in adults with hepatorenal syndrome and serious liver disease. Its clinical setting and respiratory-risk precautions are central to interpreting the trial results.
MedlinePlus describes use to improve kidney function in adults with hepatorenal syndrome and serious liver disease. It is administered by healthcare professionals and carries an important warning about severe breathing problems.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Terlipressin works
It acts through vasopressin receptor pathways to alter vascular tone. The intended renal benefit is tied to the circulatory disturbance in hepatorenal syndrome, rather than a general kidney-health effect.
Source: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
Molecular structure
Questions worth asking
- Did improved kidney function mean better survival?
- What population, comparator, and route were actually studied?
- Improvement in the specified kidney-function endpoint did not demonstrate a survival advantage. Serious respiratory harms are essential context for the result.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did improved kidney function mean better survival?
No survival advantage was demonstrated in this trial. The kidney endpoint and respiratory complications must both be considered.
Source: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · 2021 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
